^
Association details:
| Biomarker: | EGFR mutation + CTBP2 rs376695472 |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
Published date:
07/29/2023
Excerpt:
We sequenced tumor exomes from 135 lung cancer patients (79 with EGFR-wildtype (WT), 56 with EGFR-mutant tumors) enrolled in the ALCAPONE trial...Two SNPs were found in the CTBP2 gene: rs376695472 (c.2036 T > C, p.(Ile679Thr)) and rs945665113 (c.2059C > T, p.(Arg687Trp)), and both of them were associated with a better PFS of patients receiving EGFR TKI treatment (HR = 0.36 [0.19–0.67]; p = 0.0009 and HR = 0.39 [0.22–0.70]; p = 0.0012).
DOI:
https://doi.org/10.1186/s12943-023-01829-4
Trial ID:
